These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8170171)

  • 21. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.
    Trifilio S; Zhou Z; Mehta J; Czerniak C; Pi J; Greenberg D; Koslosky M; Pantiru M; Altman J
    Leuk Res; 2013 Aug; 37(8):868-71. PubMed ID: 23726414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics of idarubicin.
    Robert J
    Clin Pharmacokinet; 1993 Apr; 24(4):275-88. PubMed ID: 8491056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
    Speth PA; Minderman H; Haanen C
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):2-9. PubMed ID: 2648580
    [No Abstract]   [Full Text] [Related]  

  • 26. Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
    Hempel G; Haberland S; Schulze-Westhoff P; Möhling N; Blaschke G; Boos J
    J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):287-92. PubMed ID: 9367219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.
    Paul C; Tidefelt U; Liliemark J; Peterson C
    Leuk Res; 1989; 13(2):191-6. PubMed ID: 2927175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
    Fujita H; Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):791-8. PubMed ID: 1605655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
    Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
    Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of idarubicinol on the antileukemic effect of idarubicin.
    Fukushima T; Kawai Y; Urasaki Y; Yoshida A; Ueda T; Nakamura T
    Leuk Res; 1994 Dec; 18(12):943-7. PubMed ID: 7996875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
    Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
    Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idarubicin: an anthracycline antineoplastic agent.
    Cersosimo RJ
    Clin Pharm; 1992 Feb; 11(2):152-67. PubMed ID: 1551297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
    Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
    J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of apoptosis by idarubicin: how important is the plasma peak?
    Gieseler F; Clark M; Stiebeling K; Puschmann M; Valsamas S
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):217-21. PubMed ID: 10783832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
    Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Cerri R; Risso M; Damasio E; Rossi E
    Cancer; 1985 Apr; 55(7):1452-4. PubMed ID: 3856461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma.
    de Graaf SS; Riley-Stewart CA; Evans WE
    J Chromatogr; 1989 Jul; 491(2):501-6. PubMed ID: 2808635
    [No Abstract]   [Full Text] [Related]  

  • 38. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
    Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
    Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
    Bogush T; Robert J
    Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.